Dai J, Zheng S, Falco M, Bao J, Eriksson J, Pikkusaari S
Nat Commun. 2024; 15(1):1158.
PMID: 38326354
PMC: 10850087.
DOI: 10.1038/s41467-024-45478-7.
Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz S, Piseddu I
Cancers (Basel). 2022; 14(21).
PMID: 36358659
PMC: 9655638.
DOI: 10.3390/cancers14215240.
Bolgi O, Silva-Garcia M, Ross B, Pilla E, Kari V, Killisch M
EMBO Rep. 2022; 23(10):e54136.
PMID: 35912982
PMC: 9535758.
DOI: 10.15252/embr.202154136.
Yoshimatsu S, Nakajima M, Qian E, Sanosaka T, Sato T, Okano H
Cells. 2022; 11(3).
PMID: 35159172
PMC: 8834151.
DOI: 10.3390/cells11030360.
Brnich S, Arteaga E, Wang Y, Tan X, Berg J
J Mol Diagn. 2021; 23(7):847-864.
PMID: 33964450
PMC: 8491091.
DOI: 10.1016/j.jmoldx.2021.04.010.
Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.
Sadeghi F, Asgari M, Matloubi M, Ranjbar M, Karkhaneh Yousefi N, Azari T
Biol Proced Online. 2020; 22:23.
PMID: 33013205
PMC: 7528506.
DOI: 10.1186/s12575-020-00133-5.
A Functional Analysis of the Unclassified Pro2767Ser BRCA2 Variant Reveals Its Potential Pathogenicity that Acts by Hampering DNA Binding and Homology-Mediated DNA Repair.
Esposito M, Minopoli G, Esposito L, DArgenio V, Di Maggio F, Sasso E
Cancers (Basel). 2019; 11(10).
PMID: 31569370
PMC: 6826418.
DOI: 10.3390/cancers11101454.
Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis.
De Toni E, Ziesch A, Rizzani A, Torok H, Hocke S, Lu S
Oncotarget. 2016; 7(8):9477-90.
PMID: 26843614
PMC: 4891053.
DOI: 10.18632/oncotarget.7053.
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.
Chiorean E, Coveler A
Drug Des Devel Ther. 2015; 9:3529-45.
PMID: 26185420
PMC: 4500614.
DOI: 10.2147/DDDT.S60328.
Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth.
Mainetti L, Zhe X, Diedrich J, Saliganan A, Cho W, Cher M
Int J Cancer. 2014; 136(1):11-20.
PMID: 24798488
PMC: 4199873.
DOI: 10.1002/ijc.28948.
DNA damage response genes and the development of cancer metastasis.
Broustas C, Lieberman H
Radiat Res. 2014; 181(2):111-30.
PMID: 24397478
PMC: 4064942.
DOI: 10.1667/RR13515.1.
RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis.
Yang G, Mercado-Uribe I, Multani A, Sen S, Shih I, Wong K
Int J Cancer. 2013; 133(2):275-85.
PMID: 23319376
PMC: 3883442.
DOI: 10.1002/ijc.28032.
Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.
Arbini A, Greco M, Yao J, Bourne P, Marra E, Hsieh J
Am J Pathol. 2011; 178(5):2367-76.
PMID: 21514447
PMC: 3081144.
DOI: 10.1016/j.ajpath.2011.01.050.
Nodal and activin receptor-like kinase 7 induce apoptosis in human breast cancer cell lines: Role of caspase 3.
Zhong Y, Xu G, Ye G, Lee D, Modica-Amore J, Peng C
Int J Physiol Pathophysiol Pharmacol. 2011; 1(1):83-96.
PMID: 21383881
PMC: 3040937.
Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.
Yang G, Chang B, Yang F, Guo X, Cai K, Xiao X
Clin Cancer Res. 2010; 16(12):3171-81.
PMID: 20423983
PMC: 2930838.
DOI: 10.1158/1078-0432.CCR-09-3171.
DNA double strand break repair and its association with inherited predispositions to breast cancer.
Scott R
Hered Cancer Clin Pract. 2010; 2(1):37-43.
PMID: 20233482
PMC: 2839992.
DOI: 10.1186/1897-4287-2-1-37.
Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells.
Misra S, Sharma S, Agarwal A, Khedkar S, Tripathi M, Mittal M
Mol Cancer. 2010; 9:50.
PMID: 20202217
PMC: 2842238.
DOI: 10.1186/1476-4598-9-50.
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.
Evers B, Schut E, van der Burg E, Braumuller T, Egan D, Holstege H
Clin Cancer Res. 2009; 16(1):99-108.
PMID: 20008842
PMC: 2802735.
DOI: 10.1158/1078-0432.CCR-09-2434.
Novel BRCA2-interacting protein BJ-HCC-20A inhibits the induction of apoptosis in response to DNA damage.
Tomiyoshi G, Nakanishi A, Takenaka K, Yoshida K, Miki Y
Cancer Sci. 2008; 99(4):747-54.
PMID: 18307534
PMC: 11158996.
DOI: 10.1111/j.1349-7006.2008.00733.x.
Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9.
Moro L, Arbini A, Yao J, di Santagnese P, Marra E, Greco M
Cancer Sci. 2008; 99(3):553-63.
PMID: 18167127
PMC: 11158040.
DOI: 10.1111/j.1349-7006.2007.00719.x.